Senti Biosciences Holdings, Inc. 10-K/A: Investor Analysis
Senti Biosciences Holdings, Inc. Files 10-K/A Amendment: Key Investor Highlights
Overview & Purpose of Filing
Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This amendment was made to provide information required by Part III (Items 10, 11, 12, 13, and 14) of Form 10-K, as the company will not file its definitive proxy statement within 120 days following its fiscal year end.
This filing also reflects a holding company reorganization completed on April 24, 2026, which may impact the company’s structure and reporting obligations going forward.
Key Financial and Shareholder Data
- Market Capitalization: As of June 30, 2025, the aggregate market value of common stock held by non-affiliates was approximately \$53.2 million (based on Nasdaq closing price).
- Shares Outstanding: As of April 22, 2026, there were 31,754 shares of common stock (par value \$0.0001) outstanding.
- Reverse Stock Split: All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse stock split effected on July 17, 2024.
- Reporting Status: Senti is a non-accelerated filer and a smaller reporting company. It is not a well-known seasoned issuer, nor a shell company, and has complied with all SEC reporting and interactive data requirements.
Corporate Governance & Board Changes
- Board of Directors includes Timothy Lu, M.D., Ph.D. (CEO, President, Director), Jay Cross (CFO), Edward Mathers, and James J. Collins, Ph.D.
- Committee structure:
- Audit Committee: Oversees corporate accounting, financial reporting, and internal controls. Chair: Edward Mathers.
- Compensation Committee: Oversees executive compensation, plans, and awards. Chair: James J. Collins, Ph.D.
- Nominating & Corporate Governance Committee: Focuses on board composition, governance, and director education.
- Director Attendance: Four directors attended the 2025 annual shareholder meeting.
Executive Compensation Details
2025 CEO Compensation (Timothy Lu, M.D., Ph.D.):
- Salary: \$465,000
- Stock Awards: \$2,893,857
- Option Awards: Not specified for 2025
- Performance-based cash bonus: Amount TBD (to be determined in Q2 2026)
- Other Compensation: Employer 401(k) match
2025 CFO Compensation (Jay Cross):
- Salary: \$465,000
- Stock Awards: \$547,540
- Option Awards: Not specified for 2025
- Performance-based cash bonus: Amount TBD
- Other Compensation: Employer 401(k) match
Director Compensation: Cash retainers and fees for committee roles are as follows:
| Role |
Annual Fee (\$) |
| Audit Committee Chairperson |
15,000 |
| Audit Committee Member |
7,500 |
| Compensation Committee Chairperson |
15,000 |
| Compensation Committee Member |
7,500 |
| Nominating and Corporate Governance Chairperson |
4,000 |
| Nominating and Corporate Governance Member |
4,000 |
Directors also receive equity awards as part of their compensation.
Performance bonuses for the executive team for 2025 are not yet determined and may be announced in Q2 2026. This could be price sensitive once disclosed.
Compensation Recovery & Insider Policies
- Senti has a compensation recovery policy (effective October 2, 2023) requiring clawback of incentive-based compensation if financial statements are restated for material noncompliance.
- Strict insider trading policy prohibits executive officers and directors from trading on material nonpublic information, hedging, pledging, or using company securities as collateral.
- No executive officers or directors have engaged in hedging or pledging transactions involving company securities to date.
Any restatement of financials could trigger compensation clawbacks, potentially impacting executive payouts and share price.
Other Price-Sensitive Information
- Holding Company Reorganization: On April 24, 2026, Senti Biosciences, Inc. implemented a holding company structure. Former Senti is now a wholly owned subsidiary of the new holding company. This may impact future corporate actions, reporting, and strategic flexibility.
- Reverse Stock Split: The 1-for-10 reverse split reduces the number of shares outstanding, potentially affecting share price, liquidity, and compliance with Nasdaq listing standards.
- Pension and Retirement Benefits: No executive officers participated in or received benefits under any pension or defined benefit plan in 2025.
Risk Management & Governance Practices
- Board and committees actively oversee risk management, compliance, and internal controls.
- Audit Committee oversees whistleblower hotline (+1 (844) 982-1781) for reporting accounting or audit concerns.
- Code of Business Conduct and Ethics applies to all directors, officers, and employees, and is available on Senti’s website.
Forward-Looking Statements & Caution
The report contains forward-looking statements regarding plans, strategies, and prospects. These statements are subject to risks and uncertainties, and actual results may differ materially from projections. Investors are cautioned not to place undue reliance on these statements, which are only current as of the filing date.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. The information above is based on Senti Biosciences Holdings, Inc.’s 10-K/A filing for the period ending December 31, 2025. Investors should conduct their own due diligence and consult their financial advisors before making investment decisions. Future events, corporate actions, or financial restatements may materially impact the company’s share price.
View Senti Biosciences, Inc. Historical chart here
